HighTower Advisors LLC trimmed its holdings in Haleon PLC Sponsored ADR (NYSE:HLN – Free Report) by 37.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 140,637 shares of the company’s stock after selling 84,770 shares during the quarter. HighTower Advisors LLC’s holdings in Haleon were worth $1,422,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Atlantic Union Bankshares Corp raised its holdings in shares of Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after buying an additional 2,758 shares during the last quarter. Stance Capital LLC bought a new position in shares of Haleon in the third quarter valued at about $34,000. Geneos Wealth Management Inc. raised its holdings in shares of Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after buying an additional 1,203 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Haleon by 26.6% in the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock valued at $60,000 after buying an additional 1,252 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in Haleon by 428.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after purchasing an additional 5,124 shares during the period. 6.67% of the stock is owned by institutional investors.
Haleon Stock Performance
Shares of NYSE:HLN opened at $8.72 on Thursday. The stock has a market capitalization of $38.61 billion, a P/E ratio of 22.35, a P/E/G ratio of 1.98 and a beta of 0.13. Haleon PLC Sponsored ADR has a 1-year low of $8.65 and a 1-year high of $11.28. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. The business has a 50-day moving average price of $9.45 and a two-hundred day moving average price of $9.94.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on the company. Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy”.
Read Our Latest Report on Haleon
Haleon Company Profile
Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.
Featured Articles
- Five stocks we like better than Haleon
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
- Palo Alto Networks Accelerates Growth 31% on AI Demand
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
